Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.32 - $0.5 $3,853 - $6,021
-12,042 Reduced 69.99%
5,164 $1,000
Q3 2022

Nov 14, 2022

SELL
$0.4 - $0.59 $690 - $1,018
-1,726 Reduced 9.12%
17,206 $7,000
Q2 2022

Aug 15, 2022

SELL
$0.44 - $0.97 $49 - $108
-112 Reduced 0.59%
18,932 $10,000
Q1 2022

May 16, 2022

BUY
$0.82 - $1.13 $9,827 - $13,543
11,985 Added 169.78%
19,044 $19,000
Q4 2021

Feb 14, 2022

BUY
$0.92 - $2.2 $763 - $1,826
830 Added 13.32%
7,059 $7,000
Q3 2021

Nov 15, 2021

SELL
$2.15 - $3.92 $836 - $1,524
-389 Reduced 5.88%
6,229 $15,000
Q2 2021

Aug 16, 2021

BUY
$3.75 - $5.17 $24,817 - $34,215
6,618 New
6,618 $26,000

Others Institutions Holding LMNL

About Liminal BioSciences Inc.


  • Ticker LMNL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,042,600
  • Description
  • Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the trea...
More about LMNL
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.